This educational series explores evolving strategies in the management of acute myeloid leukemia (AML) with a focus on targeted therapies. Faculty experts will review molecular diagnostics and guideline-driven use of FLT3 and menin inhibitors across treatment lines, including frontline, relapsed/refractory, and maintenance settings. Participants will examine clinical trial data, adverse event management, and practical applications through real-world case discussions. The activity emphasizes evidence-based sequencing, MRD assessment, and safety monitoring to support optimal patient outcomes.